SCHEMBL21965752

SCHEMBL21965752

CN1CCN(c2ccc(NC(C)(C)C)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 4/20 0.53
ALDH1A1 P00352 3/20 0.53
KMT2A Q03164 3/20 0.53
GAA P10253 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPT P10636 1/20 0.53
GFER P55789 1/20 0.53
PTK2B Q14289 1/20 0.53
ESR2 Q92731 1/20 0.53
MEN1 O00255 2/20 0.51
ADRA2A P08913 3/20 0.50
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
ADRA2B P18089 2/20 0.47
KDM1A O60341 1/20 0.47
GLA P06280 1/20 0.47
SLC2A1 P11166 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24590328 0.85 MAPT (0.57) ALDH1A1KMT2AGAAKDM4EMAPT
SCHEMBL22742655 0.84 HTR3A (0.59) ADRA2CALDH1A1KMT2AGAAKDM4E
SCHEMBL12233671 0.83 MAPT (0.56) ALDH1A1KMT2AGAAKDM4EMAPT
SCHEMBL7898243 0.82 RAD52 (0.59) ADRA2CKMT2AGAAKDM4EMAPT
SCHEMBL12205820 0.81 MAPT (0.52) ALDH1A1KMT2AGAAKDM4EMAPT
SCHEMBL24590132 0.81 ALDH1A1 (0.53) ALDH1A1KMT2AGAAKDM4EMAPT
SCHEMBL21965377 0.80 ADRB1 (0.56) ALDH1A1KDM4EKDM1ASIRT6NCF1
SCHEMBL13994004 0.80 ADRA2C (0.56) ADRA2CALDH1A1GAAKDM4EMAPT
SCHEMBL24590135 0.79 SMN1; SMN2 (0.57) ALDH1A1KMT2AGAAKDM4EMAPT
SCHEMBL31009022 0.79 MAPT (0.41) ALDH1A1KMT2AGAAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 US disclosed
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 US disclosed
US-20200339596-A1 FUROXAN-BASED COMPOUNDS AND USES THEREOF UNIVERSITY OF MASSACHUSETTS 2020-10-29 US disclosed
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339596-A1 FUROXAN-BASED COMPOUNDS AND USES THEREOF PARK7, HTT, PRDX5 ADRA2C 2359/4885ALDH1A1 1029/4885KMT2A 3147/4885
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation CRBN, CBL, STUB1 ADRA2C 4117/4885ALDH1A1 4548/4885KMT2A 1996/4885
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBL, STUB1 ADRA2C 4117/4885ALDH1A1 4548/4885KMT2A 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.